tiprankstipranks
Trending News
More News >

Blueprint Medicines price target raised to $129 from $102 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Blueprint Medicines (BPMC) to $129 from $102 and keeps an Equal Weight rating on the shares. The key upside risk to the firm’s Equal Weight rating has played out with Sanofi’s (SNY) announced acquisition of Blueprint for $129 per share plus a non-tradeable CVR of up to $6 per share, the analyst tells investors in a research note.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue